
UK NEQAS

Leucocyte Immunophenotyping







2026 - 2027 Full Programme List - EQA/PT Programmes for Flow Cytometry and Molecular Haemato-Oncology

Flow Cytometry Programmes

- CD19 CAR-T Cell Monitoring by Flow Cytometry*
- CD34+ Stem Cell Enumeration
- Cerebrospinal Fluid (CSF) Immunophenotyping*
- Competency Assessment and Instrument Validation Panel for Immune Monitoring
- Haematological Malignancy Bone Marrow Aspirate Assessment*
- Immune Monitoring
- Leukaemia Diagnostic Interpretation
- Leukaemia Immunophenotypina
- Low Level Leucocyte Enumeration
- Measurable Residual Disease for ALL by Flow Cytometry
- Measurable Residual Disease for AML by Flow Cytometry*
- Measurable Residual Disease for CLL by Flow Cvtometry*
- Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry*
- Paroxysmal Nocturnal Haemoglobinuria

Molecular Haemato-Oncology Programmes

- BCR::ABL1 and AML Translocation Identification
- BCR::ABL1 Kinase Domain Variant (Mutation) Status
- BCR::ABL1 Major Quantification
- BCR::ABL1 Minor Quantification
- BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia
- FLT3 Mutation Status
- IG/TCR Clonality Status
- KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease
- Lymphoid Gene Panels*
- Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulingemia
- Measurable Residual Disease for AML by Molecular Methods*
- Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods*
- Myeloid Gene Panels*
- Myeloproliferative Neoplasms
 Diagnostic Testing**
- NPM1 Mutation Status
- Paediatric Acute Leukaemia Translocations
- Post-Stem Cell Transplant Chimerism Monitoring

Should you wish to participate in any of the above programmes please contact:

UK NEQAS LI
Pegasus House
4th Floor Suite
463a Glossop Road
Sheffield \$10 2QD
United Kinadom

Tel: +44 (0)114 2673600 Fax: +44 (0)114 2673601

email: admin@ukneqasli.co.uk www.ukneqasli.co.uk

Please note that if your participation with UK NEQAS LI is via a non-UK distributor you should contact them directly for details of how to register. If you are enquiring from outside of the UK your registration will be managed by EQA International Ltd.

^{**} Please note that the JAK2 p.Val617Phe Mutation Status programme is now incorporated within the Myeloproliferative Neoplasms Diagnostic Testing programme. Accreditation of the remaining markers is anticipated by the end of 2026.